资源 » 参考数据库 » 客户发表文献

至今，GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次，处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果，再次证明GenScript 有能力帮助业内科学家Make research easy.

Evaluating a Potential Dose-Sparing Self-Amplifying RNA Vaccine for Induction of Functional Antibodies to Blood-Stage Plasmodium falciparum Malaria

Vaccines. 2026-10; 
Adam Thomas, Timothy K. C. Ho, Sandra Chishimba, Liriye Kurtovic, Tom Rünz, Claretta S. D’Souza, James G. Beeson Burnet Institute, Melbourne, VIC 3004, Australia; timothy.ho@student.burnet.edu.au (T.K.C.H.);
Products/Services Used Details Operation
Custom mRNA synthesis The saRNA synthesis, LNP formulation, and characterisation were performed by GenScript Biotech, Sydney, Australia (Table S1). Get A Quote

摘要

Introduction: Next-generation malaria vaccines are urgently needed to provide greater efficacy and longevity. Antibodies targeting blood-stage merozoites can confer protection against clinical malaria through multiple Fmediated functions. In particular, merozoite surface protein 2 (PfMSP2) is a known target of protective antibodies that can clear merozoites via multiple antibody Fc-mediated functions, making it a highly promising vaccine candidate. M

关键词

functional antibodies; malaria; vaccine; merozoite surface protein 2; complement; Fc-receptors; saRNA
Article Link >